Central States Research

Tulsa, Oklahoma 74136

5 studies enrolling now · 23 studies all time

What they study most

Acute Treatment of Migraine, Alzheimer Disease, Alzheimer's Disease, Atopic Dermatitis, Cardiovascular Diseases, Chronic Kidney Disease, Cognition Disorders, Dementia, Diabetes Mellitus, Type 2, Fragile X Syndrome, Mild Cognitive Impairment, Obesity

Studies at this site

• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — Recruiting now
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) — Recruiting now
• A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine — Recruiting now
• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) — Running, not enrolling
• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes — Starting soon
• Alzheimer's Disease Neuroimaging Initiative 4 — Enrolling by invitation
• Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS — Running, not enrolling
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) — Running, not enrolling
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes — Withdrawn before enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis — Completed
• A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) — Stopped early
• Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging — Completed
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study of Gantenerumab in Participants With Mild Alzheimer Disease — Completed
• Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early